Tag:

ASP015K

Latest Headlines

Latest Headlines

J&J, Astellas strike potential $945M deal for oral RA drug

A Johnson & Johnson unit has gained a potential new weapon in the fight against rheumatoid arthritis (RA), agreeing to lay down $65 million upfront to gain rights to an oral JAK inhibitor from Astellas Pharma for all markets outside of Japan, Astellas reported.